We specialize in Actovegin injections and tablets wholesale (bulk orders)
If you need any quantity, feel free to contact us.
We can ship up to 50 boxes in one parcel. Regular delivery time is approximately 10–12 days.
We will offer you the best price possible for any quantity. You can buy Actovegin with delivery to any country, except Norway and Denmark.
Actovegin® is one of the best-selling drugs in the CIS region. Over 40 years ago, specialists at the Austrian branch of Nycomed discovered a substance that significantly influences intracellular processes and supports cellular metabolism.
Thanks to collaboration between Nycomed (now part of the Japanese pharmaceutical company Takeda) and Warsaw Pact countries, Actovegin® was officially registered in West Germany in 1976. It was introduced in the USSR in 1984 and quickly gained popularity. Today, it is produced in Linz (Austria), Oranienbaum (Germany), and Yaroslavl (Russia), and registered in 22 countries including Austria, Latvia, Romania, and several Asian nations.
Company Information
Takeda is one of the world’s 15 largest pharmaceutical companies, employing over 29,000 people. Its key areas include cardiovascular diseases, oncology, gastroenterology, respiratory disorders, immunology, and neurology.
Indications for Use
Actovegin® is a deproteinized ultrafiltrate of calf blood containing over 200 biologically active substances. It is used in ischemic and metabolic brain disorders, stroke, encephalopathy, peripheral arterial/venous circulation disorders, and diabetic polyneuropathy.
Preclinical studies show improved glucose and oxygen uptake, enhanced energy metabolism, and increased ATP production. Actovegin demonstrates neuroprotective effects, such as increased neuron survival, improved synaptic function, reduced oxidative stress, and inhibition of apoptosis.
It also promotes microcirculation, improves vascular endothelial function, and is effective in treating stroke, chronic cerebral ischemia, and diabetic polyneuropathy.
Clinical Studies
Evidence-based medicine in Kazakhstan and other countries requires robust clinical trials. The Cochrane Library lists 48 publications on Actovegin®, and PubMed features 137. Key studies include:
- Actovegin in dementia (Donoghue, Liverpool, UK) — Level 1A evidence
- Actovegin vs placebo in diabetic polyneuropathy (Ziegler et al., Diabetes Care 2009) — Level 1B evidence
The ARTEMIDA study (2017), a 12-month international randomized double-blind placebo-controlled trial, evaluated Actovegin’s effectiveness for post-stroke cognitive impairment (PACI). Published in Stroke, a top-tier neurology journal, it involved 503 patients across Russia, Belarus, and Kazakhstan.
Patients received either Actovegin (2000 mg IV infusion + 1200 mg/day oral) or placebo for 6 months, followed by 6 months of observation. Primary endpoint: ADAS-Cog+ score change at 6 months. Secondary endpoints: changes at 3/12 months, MoCA score shifts, number of responders.
Results showed significant cognitive improvement with Actovegin, sustained beyond the treatment period. After 3 months, measurable benefits were already evident. By study end, dementia diagnoses were 30% lower in the Actovegin group. Adverse event rates were comparable across both groups.
Conclusion: ARTEMIDA’s results support including Actovegin® among a select group of medications with strong evidence for treating cognitive disorders. (Prof. Vladimir Zakharov, Sechenov University)